Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C2583
http://purl.obolibrary.org/obo/NCIT_C2583
|
|---|---|
| Preferred Name | Rosiglitazone Maleate |
| Definitions |
The maleate salt of rosiglitazone, an orally-active thiazolidinedione with antidiabetic properties and potential antineoplastic activity. Rosiglitazone activates peroxisome proliferator-activated receptor gamma (PPAR-gamma), a ligand-activated transcription factor, thereby inducing cell differentiation and inhibiting cell growth and angiogenesis. This agent also modulates the transcription of insulin-responsive genes, inhibits macrophage and monocyte activation, and stimulates adipocyte differentiation.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | The maleate salt of rosiglitazone, an orally-active thiazolidinedione with antidiabetic properties and potential antineoplastic activity. Rosiglitazone activates peroxisome proliferator-activated receptor gamma (PPAR-gamma), a ligand-activated transcription factor, thereby inducing cell differentiation and inhibiting cell growth and angiogenesis. This agent also modulates the transcription of insulin-responsive genes, inhibits macrophage and monocyte activation, and stimulates adipocyte differentiation. |
|---|---|
| label | Rosiglitazone Maleate
|
| prefLabel | Rosiglitazone Maleate
|
| Has_Free_Acid_Or_Base_Form | |
| Legacy Concept Name | Rosiglitazone
|
| in_subset |
See more
See less
|
| Preferred_Name | Rosiglitazone Maleate
|
| Is_Value_For_GDC_Property | |
| Chemical_Formula | C18H19N3O3S.C4H4O4
|
| Display_Name | Rosiglitazone Maleate
|
| Maps_To | Rosiglitazone Maleate
|
| PDQ_Open_Trial_Search_ID | 37793
|
| Has_Target | |
| UMLS_CUI | C0795660
|
| FDA_UNII_Code | KX2339DP44
|
| prefixIRI | NCIT:C2583
|
| Accepted_Therapeutic_Use_For |
Type 2 diabetes
Non-Insulin-Dependent Diabetes Mellitus and Type II Diabetes Mellitus
|
| NCI_Drug_Dictionary_ID | 37793
|
| Contributing_Source |
CTRP
FDA
|
| subClassOf | |
| CHEBI_ID | CHEBI:8892
|
| code | C2583
|
| type | |
| ALT_DEFINITION | A drug that helps control the amount of glucose (sugar) in the blood and is being studied in the prevention and treatment of some types of cancer. Avandia stops cells from growing and may prevent the growth of new blood vessels that tumors need to grow. It is a type of thiazolidinedione and a type of antiangiogenesis agent.
|
| NSC Number | 717764
|
| PDQ_Closed_Trial_Search_ID | 37793
|
| Semantic_Type | Pharmacologic Substance
|
| CAS_Registry | 155141-29-0
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |